Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ALDX – Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.
ALDX
$1.79
Name : Aldeyra Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $106,580,024.00
EPSttm : -0.94
finviz dynamic chart for ALDX
Aldeyra Therapeutics, Inc.
$1.79
5.56%
$0.105

Float Short %

6.89

Margin Of Safety %

Put/Call OI Ratio

0.29

EPS Next Q Diff

0.88

EPS Last/This Y

0.77

EPS This/Next Y

-0.38

Price

1.9

Target Price

8.57

Analyst Recom

1

Performance Q

-63.79

Relative Volume

13.24

Beta

1.11

Ticker: ALDX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-10ALDX6.620.380.0129649
2025-03-11ALDX6.930.370.1230318
2025-03-12ALDX6.990.360.6830744
2025-03-13ALDX6.820.360.0130507
2025-03-14ALDX6.910.360.3430613
2025-03-17ALDX6.280.360.7530993
2025-03-18ALDX6.680.370.3731269
2025-03-19ALDX6.580.380.1031322
2025-03-20ALDX6.720.370.4331671
2025-03-21ALDX6.580.370.0531751
2025-03-24ALDX6.610.400.2527083
2025-03-25ALDX6.690.400.9327616
2025-03-26ALDX6.30.410.1028030
2025-03-27ALDX6.280.390.1129338
2025-03-28ALDX6.680.380.2030086
2025-03-31ALDX5.720.370.1831002
2025-04-01ALDX5.470.360.1632878
2025-04-02ALDX5.330.330.8237613
2025-04-03ALDX1.450.370.5540990
2025-04-04ALDX1.90.290.0443210
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-10ALDX6.62-89.3- -0.92
2025-03-11ALDX6.94-89.3- -0.92
2025-03-12ALDX7.00-89.3- -0.92
2025-03-13ALDX6.82-89.3- -0.92
2025-03-14ALDX6.91-89.3- -0.27
2025-03-17ALDX6.31-68.6- -0.27
2025-03-18ALDX6.66-68.6- -0.27
2025-03-19ALDX6.58-68.6- -0.27
2025-03-20ALDX6.72-68.6- -0.27
2025-03-21ALDX6.60-68.6- -0.27
2025-03-24ALDX6.61-68.6- -0.27
2025-03-25ALDX6.68-68.6- -0.27
2025-03-26ALDX6.30-68.6- -0.27
2025-03-27ALDX6.26-68.6- -0.27
2025-03-28ALDX6.67-68.6- -0.27
2025-03-31ALDX5.72-68.6- -0.27
2025-04-01ALDX5.47-68.6- -0.27
2025-04-02ALDX5.32-68.6- -0.27
2025-04-03ALDX1.42-68.6- -0.17
2025-04-04ALDX1.90-68.6- -0.17
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-10ALDX0.056.436.34
2025-03-11ALDX0.056.436.34
2025-03-12ALDX0.056.436.23
2025-03-13ALDX0.056.436.23
2025-03-14ALDX0.056.436.23
2025-03-17ALDX0.056.456.23
2025-03-18ALDX0.056.456.23
2025-03-19ALDX0.056.456.23
2025-03-20ALDX0.056.456.23
2025-03-21ALDX0.056.456.23
2025-03-24ALDX0.056.516.23
2025-03-25ALDX0.056.516.23
2025-03-26ALDX0.056.516.89
2025-03-27ALDX0.056.516.89
2025-03-28ALDX0.056.516.89
2025-03-31ALDX0.056.496.89
2025-04-01ALDX0.056.496.89
2025-04-02ALDX0.056.496.89
2025-04-03ALDX0.056.496.89
2025-04-04ALDX0.056.496.89
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.27

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

0.61

Insider Transactions

0.05

Institutional Transactions

6.49

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

54

Fair Value

Quality Score

13

Growth Score

18

Sentiment Score

27

Actual DrawDown %

88.1

Max Drawdown 5-Year %

-90.4

Target Price

8.57

P/E

Forward P/E

PEG

P/S

P/B

1.59

P/Free Cash Flow

EPS

-0.94

Average EPS Est. Cur. Y​

-0.17

EPS Next Y. (Est.)

-0.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

13.24

Return on Equity vs Sector %

-98.5

Return on Equity vs Industry %

-85.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.16

EBIT Estimation

Aldeyra Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 9
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
stock quote shares ALDX – Aldeyra Therapeutics, Inc. Stock Price stock today
news today ALDX – Aldeyra Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALDX – Aldeyra Therapeutics, Inc. yahoo finance google finance
stock history ALDX – Aldeyra Therapeutics, Inc. invest stock market
stock prices ALDX premarket after hours
ticker ALDX fair value insiders trading